Patents by Inventor Shahrooz Rabizadeh

Shahrooz Rabizadeh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10113160
    Abstract: Genetically engineered cells and methods are presented that allow for the production of various value products from CO2. Contemplated cells have a CBB cycle that is genetically modified such that two molecules of CO2 fixed in the CBB cycle can be withdrawn from the modified CBB cycle as a single C2 compound. In contemplated aspects a CBB cycle includes an enzymatic activity that generates the single C2 compound from a compound of the CBB cycle, while further modifications to the CBB cycle will not introduce additional recombinant enzymatic activity/activities outside the already existing catalytic activities in the CBB cycle.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: October 30, 2018
    Assignee: Easel Biotechnologies, LLC
    Inventors: Yi-Xin Huo, Benjamin Schilling, Shahrooz Rabizadeh
  • Patent number: 10106825
    Abstract: Systems, methods, and metabolically engineered microorganisms are contemplated in which low molecular weight gases, and especially methane and syngas are used as a carbon source, and in which CO2 or formaldehyde and reduction equivalents are generated for use in in vivo production of the value products.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: October 23, 2018
    Assignee: Easel Biotechnologies, LLC
    Inventors: Yi-Xin Huo, Lars Erik Ulf Rohlin, Shahrooz Rabizadeh
  • Patent number: 10076529
    Abstract: Compositions, compounds, and methods with significant antiviral effect against RNA viruses and especially orthomyxoviruses are contemplated, and target the viral promoter that is formed by the 5? and 3?-UTR sequences of the viral genome.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: September 18, 2018
    Assignee: NANT HOLDINGS IP, LLC
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Anne-Laure Le Ny, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong
  • Publication number: 20180258501
    Abstract: Systems and methods are provided for determination of primers for differentiation of at least two unspecified pathogens that belong to distinct pathogen (e.g., virus) families that comprise multiple distinct pathogen species and/or varieties.
    Type: Application
    Filed: November 20, 2015
    Publication date: September 13, 2018
    Inventors: Shahrooz Rabizadeh, Kayvan Niazi, Stephen Charles Benz, Andrew Nguyen
  • Publication number: 20180216096
    Abstract: Genetically engineered cells and methods are presented that allow for the production of various value products from CO2. Contemplated cells have a CBB cycle that is genetically modified such that two molecules of CO2 fixed in the CBB cycle can be withdrawn from the modified CBB cycle as a single C2 compound. In contemplated aspects a CBB cycle includes an enzymatic activity that generates the single C2 compound from a compound of the CBB cycle, while further modifications to the CBB cycle will not introduce additional recombinant enzymatic activity/activities outside the already existing catalytic activities in the CBB cycle.
    Type: Application
    Filed: March 28, 2018
    Publication date: August 2, 2018
    Inventors: Yi-Xin Huo, Benjamin Schilling, Shahrooz Rabizadeh
  • Publication number: 20180185335
    Abstract: Various compounds, compositions, and methods for inhibition of Rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with Rit1 signaling.
    Type: Application
    Filed: June 29, 2016
    Publication date: July 5, 2018
    Applicant: NANTBIO, INC.
    Inventors: Shahrooz RABIZADEH, Oleksandr BUZKO, Paul WEINGARTEN, Heather MCFARLANE, Connie TSAI, Stephen Charles BENZ, Kayvan NIAZI, Patrick SOON-SHIONG
  • Publication number: 20180172690
    Abstract: Methods are provided for determining the diagnosis of whether a liver mass is a benign hepatocellular adenoma or a pre-malignant hepatocellular dysplastic nodule and/or a malignant hepatocellular carcinoma. Specific protein fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in liver mass cells collected from liver mass tissue that was obtained from a patient suffering from the liver mass and compared to reference levels in order to determine if the liver mass is a benign growth or a pre-cancer and/or cancer.
    Type: Application
    Filed: April 20, 2017
    Publication date: June 21, 2018
    Inventors: Shahrooz RABIZADEH, Todd HEMBROUGH, Fabiola CECCHI, Christina YAU, David KRIZMAN, Wei-Li Liao, Sheeno Thyparambil
  • Publication number: 20180170942
    Abstract: Contemplated compounds, compositions and methods are directed to Ral GTPase inhibitors with improved activity.
    Type: Application
    Filed: June 16, 2016
    Publication date: June 21, 2018
    Inventors: Chunlin Tao, Chengzhi Yu, Tulay Polat, Chao Yan, Shahrooz Rabizadeh, Daniel Theodorescu
  • Patent number: 9987282
    Abstract: Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent of other influenza A components. Preferred assays allow for identification of viral replication inhibitors that do not disrupt normal cellular activity.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: June 5, 2018
    Assignee: NANT HOLDINGS IP, LLC
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Anne-Laure LeNy, Oleksandr Buzko, Justin Golovato, Patrick Soon-Shiong
  • Publication number: 20180144261
    Abstract: Techniques are provided for predicting DNA accessibility. DNase-seq data files and RNA-seq data files for a plurality of cell types are paired by assigning DNase-seq data files to RNA-seq data files that are at least within a same biotype. A neural network is configured to be trained using batches of the paired data files, where configuring the neural network comprises configuring convolutional layers to process a first input comprising DNA sequence data from a paired data file to generate a convolved output, and fully connected layers following the convolutional layers to concatenate the convolved output with a second input comprising gene expression levels derived from RNA-seq data from the paired data file and process the concatenation to generate a DNA accessibility prediction output. The trained neural network is used to predict DNA accessibility in a genomic sample input comprising RNA-seq data and whole genome sequencing for a new cell type.
    Type: Application
    Filed: November 20, 2017
    Publication date: May 24, 2018
    Applicants: NantOmics, LLC., Nant Holdings IP, LLC
    Inventors: Kamil Wnuk, Jeremi Sudol, Shahrooz Rabizadeh, Patrick Soon-Shiong, Christopher Szeto, Charles Vaske
  • Publication number: 20180141998
    Abstract: Contemplated compositions and methods are directed to cancer neoepitopes and uses of such neoepitopes, especially to generate synthetic antibodies against neoepitopes that may then be employed in the manufacture of a therapeutic agent. Preferred therapeutic agents will comprise a synthetic antibody against a neoepitope, and most preferably in combination with a cellular or non-cellular component for use as a diagnostic or therapeutic agent.
    Type: Application
    Filed: April 25, 2016
    Publication date: May 24, 2018
    Inventors: Andrew Nguyen, Kayvan Niazi, Patrick Soon-Shiong, Shahrooz Rabizadeh, Stephen Charles Benz
  • Publication number: 20180128816
    Abstract: The invention generally relates to the prevention and/or treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In one embodiment, the invention involves a method comprising: a) providing a subject with tumor cells, b) removing at least a portion of said tumor cells from said subject to create removed cells, c) treating at least a portion of said removed cells ex vivo, using stimulating agents, including thapsigargin and/or thapsigargin-related compounds, so as to create treated tumor cells; and d) introducing said treated tumor cells (or fragments thereof) in vivo into the same subject to generate anticancer therapeutic effects.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 10, 2018
    Inventors: Kayvan R. Niazi, Shahrooz Rabizadeh, Dale E. Bredesen
  • Publication number: 20180117118
    Abstract: Compositions and methods are contemplated for treatment of a wound, and especially a sterile or TLR/NOD ligand-poor wound in which contemporaneous administration of a Ca2+-flux agonist (CFA) and a pattern recognition receptor (PRR) ligand improves wound healing.
    Type: Application
    Filed: December 22, 2017
    Publication date: May 3, 2018
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Oleksandr Buzko, Anne-Laure Le Ny, Patrick Soon-Shiong
  • Publication number: 20180086752
    Abstract: Compounds and compositions are presented that inhibit K-ras, and especially mutant K-ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.
    Type: Application
    Filed: April 1, 2016
    Publication date: March 29, 2018
    Inventors: Shahrooz Rabizadeh, Kayvan Niazi, Sasha Buzko, Paul Weingarten, Heather McFarlane, Anna Juncker-Jensen, Justin Golovato, Patrick Soon-Shiong, Chunlin Tao, David Ho
  • Patent number: 9885704
    Abstract: The invention generally relates to the prevention and/or treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In one embodiment, the invention involves a method comprising: a) providing a subject with tumor cells, b) removing at least a portion of said tumor cells from said subject to create removed cells, c) treating at least a portion of said removed cells ex vivo, using stimulating agents, including thapsigargin and/or thapsigargin-related compounds, so as to create treated tumor cells; and d) introducing said treated tumor cells (or fragments thereof) in vivo into the same subject to generate anticancer therapeutic effects.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: February 6, 2018
    Assignee: The Buck Institute for Age Research
    Inventors: Kayvan R. Niazi, Shahrooz Rabizadeh, Dale E. Bredesen
  • Patent number: 9884087
    Abstract: Compositions and methods are contemplated for treatment of a wound, and especially a sterile or TLR/NOD ligand-poor wound in which contemporaneous administration of a Ca2+-flux agonist (CFA) and a pattern recognition receptor (PRR) ligand improves wound healing.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: February 6, 2018
    Assignee: CHAN SOON-SHIONG NANTHEALTH FOUNDATION
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Oleksandr Buzko, Anne-Laure LeNy, Patrick Soon-Shiong
  • Publication number: 20180010155
    Abstract: Microorganisms and methods of producing n-butyraldehyde with enhanced yields are presented in which a microorganism is engineered to enhance the conversion of a carbon source into n-butyraldehyde. The n-butyraldehyde is recovered by way of a gas stripping process that occurs during the conversion process, providing significantly greater product yield than post-fermentation recovery of n-butyraldehyde alone.
    Type: Application
    Filed: September 7, 2017
    Publication date: January 11, 2018
    Applicant: Easel Biotechnologies, LLC
    Inventors: Kwang Myung Cho, Wendy Higashide, Chrissie Lee, Shahrooz Rabizadeh
  • Publication number: 20170360925
    Abstract: Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
    Type: Application
    Filed: August 31, 2017
    Publication date: December 21, 2017
    Applicant: Nant Holdings IP, LLC
    Inventors: Kayvan NIAZI, Shahrooz RABIZADEH, Justin GOLOVATO, Patrick Soon-Shiong, Anne-Laure LE NY, Oleksandr BUZKO
  • Publication number: 20170312351
    Abstract: Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate a recombinant polytope that is optimized for proper trafficking and processing. In preferred methods, the polytope is encoded in a viral expression system that is used as a therapeutic agent.
    Type: Application
    Filed: March 23, 2017
    Publication date: November 2, 2017
    Inventors: Kayvan Niazi, Andrew Nguyen, Shahrooz Rabizadeh, Patrick Soon-Shiong, Stephen Charles Benz
  • Patent number: 9789121
    Abstract: This invention provides a novel screening system for identifying p53 mimetics/agonists. Also provided are small organic molecules that act as effective p53 mimetics/agonists.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: October 17, 2017
    Assignee: BUCK INSTITUTE
    Inventors: Shahrooz Rabizadeh, Kayvan R. Niazi, Dale E. Bredesen